SCHEMBL24479569

SCHEMBL24479569

CP(=O)(O)O[C@H]1CC[C@H](C(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCON)C(=O)NCCOCCON)C(=O)NCCOCCON)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.43
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ TLR2 O60603 2/20 0.32
▸ GRIN1 Q05586 2/20 0.31
▸ GRIN2A Q12879 2/20 0.31
▸ PLG P00747 2/20 0.31
▸ PRSS1 P07477 2/20 0.31
▸ PRSS2 P07478 2/20 0.31
▸ PRSS3 P35030 2/20 0.31
▸ PLAU P00749 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNB4 P30926 1/20 0.31
▸ CHRNA3 P32297 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31
▸ GRM1 Q13255 1/20 0.31
▸ LPAR3 Q9UBY5 2/20 0.31
▸ CCKAR P32238 1/20 0.30
▸ CCKBR P32239 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18715404 1.00 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTTLR2
SCHEMBL18715377 1.00 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTTLR2
SCHEMBL24123483 0.95 GLP1R (0.38) GLP1RPOLBALDH1A1MAPTTLR2
SCHEMBL18715376 0.94 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTTLR2
SCHEMBL20800932 0.94 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTTLR2
SCHEMBL24697325 0.92 GLP1R (0.38) GLP1RPOLB
SCHEMBL24479396 0.92 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL21287423 0.92 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL20375331 0.92 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL22566716 0.92 GLP1R (0.41) GLP1RPOLBALDH1A1MAPTTLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220170015-A1 ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE Arrowhead Pharmaceuticals, Inc. (US) 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220170015-A1 ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE SERPINA2, SERPINC1, SERPINA3 GLP1R 4004/4885POLB 2045/4885ALDH1A1 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback